Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted,...
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX,...
Prescient Therapeutics update report 2024 08 29
Clinical stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) had a cash and term deposit balance of $14.5...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.